Clinical performance of cardiac Troponin I: A comparison between the POCT AQT90 FLEX and the Dimension Vista analyzer in an emergency setting

Mion, Monica; Bragato, Giada; Casarotti, Alessandra; Cosma, Chiara; Vigolo, Simonetta; Vettore, Gianna; Tosato, Franco; Zaninotto, Martina; Plebani, Mario

doi:10.1016/j.clinbiochem.2017.03.027

Cited by 14 publications

(5 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The assay is optimized on an automated platform (Dimension Vista System; Siemens Healthineers). In our laboratory, the range encompassing the 99th percentile corresponded to that reported by the manufacturer , being 0.000–0.045 ng/mL. The analytical sensitivity corresponds to 0.015 ng/mL and the functional sensitivity to 0.040 ng/mL.…”

Section: Methodssupporting

confidence: 61%

Serial Troponin for Early Detection of Nivolumab Cardiotoxicity in Advanced Non-Small Cell Lung Cancer Patients

et al. 2018

View full text Add to dashboard Cite

Myocarditis is a rare but serious adverse event of immune checkpoint blockade with nivolumab, which needs to be recognized as soon as possible. This article suggests that troponin, a user-friendly biomarker of myocardial cytotoxicity, might be useful for early detection of immune-mediated myocarditis. However, because troponin abnormalities might also be related to a number of conditions capable of causing myocardial oxygen demand-supply mismatch, a careful cardiac assessment should be performed in non-small cell lung cancer patients in order to properly interpret any troponin increase. According to the available evidence, monitoring troponin during the first weeks of treatment can be considered reasonable.

show abstract

Section: Methodssupporting

confidence: 61%

Serial Troponin for Early Detection of Nivolumab Cardiotoxicity in Advanced Non-Small Cell Lung Cancer Patients

et al. 2018

View full text Add to dashboard Cite

show abstract

“…For cTnT assays, the between-assays correlation is excellent, and strength of agreement is substantial. Our results are in accordance with those of the literature, as observed between cTnI-Vista and cTnI-AQT [14] . They highlight the fact that each cTn assay has individual analytical characteristics, and that the results are not fully transferable from one assay to another [15] , [16] .…”

Section: Discussionsupporting

confidence: 94%

“…This specificity was significantly superior to a single measurement strategy for HS-assays, cTnI-Pathfast, cTnI-Ultra and cTnI-Vista. Our results are comparable to those in the literature when considering HS assays [6] , [17] , [18] , [22] , [30] , but also cTnI Access, cTnI-Vista, cTnI-Vitros, cTnI-AQT [5] , [7] , [14] , [30] , and cTnT-AQT [19] , [30] , although comparison is limited because of the sample size of the population and study protocols (some data in the literature is reported for H0-H2). Moreover, the percentage of rule-out patients with these H0-H3 strategies is elevated for all assays.…”

Section: Discussionsupporting

confidence: 85%

Multi-centre evaluation of recent troponin assays for the diagnosis of NSTEMI

Chenevier‐Gobeaux

Deweerdt

Renaud

et al. 2018

Practical Laboratory Medicine

View full text Add to dashboard Cite

ObjectivesWe aimed to compare the use of nine different cardiac troponin (cTn) assays (2 cTnT and 7 cTnI) for the diagnosis of NSTEMI in a single multi-centre population.Design and methodsOne hundred and fifty-eight patients were included (mean age 60 years, SD 17 years), including 23 patients (14%) with NSTEMI.ResultsThe analytical comparison highlighted a large heterogeneity of cTn assays, as reflected by percentages of patients with detectable cTn, correlation coefficients, Passing-Bablok comparisons and concordance coefficients. Correlations within cTnI assays were good and correlation within cTnT assays was excellent. Diagnostic performances demonstrated that each cTn assay has specific threshold values. Furthermore, some assays (HS-cTnI and T, cTnI-Pathfast and cTnI-Centaur) indicated high sensitivity and negative predictive value using the limit of detection (LoD) diagnostic strategy. For the latter assays, a significant increase in specificity was found when using the 99th percentile or the H0-H3 strategies, in comparison to the LoD strategy. When applying the European Society of Cardiology H0-H3 algorithm, comparable diagnostic performances were obtained.ConclusionAll 9 cTn assays indicated overall good diagnostic performances for the diagnosis of NSTEMI in emergency departments when the recommended algorithm based on the variation of cTn value between two measurements at admission and 3 h later was used.

show abstract

“…A previously undertaken study by Meon et al and Herbert et al in a similar setting has reported the acceptable precision of the AQT 90 Flex analyzer considering the stringent <10% CV goal. The results of this study with a CV of 2.4% with mean cTn-I of 2.15 ± 0.05 ng/ml are in concordance with the literature [17-18]. Furthermore, the assay demonstrated acceptable linearity covering a range from 0.034 to 1.316 ng/ml to ensure a reliable clinical utility to rule out or rule in ACS.…”

Section: Discussionsupporting

confidence: 89%

Performance Evaluation of Cardiac Troponin I Assay: A Comparison Between the Point-of-care Testing Radiometer AQT90 FLEX and the Central Laboratory Siemens Advia Centaur Analyzer

Ahmed¹,

Jafri²,

Raheem³

et al. 2019

Cureus

View full text Add to dashboard Cite

Background To validate the point of care testing (POCT) Trop-I analyzer and compare it with a central laboratory-based chemiluminescence immunoassay, in order to evaluate its performance for use in critical care areas. Moreover, for clinical decision-making, it is imperative to know the extent to which patient stratification will differ based on the analytic method being used. In particular, the aim of this study was to evaluate the analytical performance of the point-of-care analyzer and demonstrate the agreement with the central laboratory measurements in patients presenting to the emergency department (ED) with chest pain and suspected acute coronary syndrome (ACS). Methods This cross-sectional study was performed at the section of chemical pathology, department of pathology and laboratory medicine, the Aga Khan University (AKU), Karachi, from October to November 2017. Samples from patients and the quality control material of Trop-I were analyzed for imprecision, linearity, and method comparison on Advia Centaur (Siemens Diagnostics, CA, USA), and the AQT90 FLEX analyzer (Radiometer Medical ApS, Brønshøj, Denmark) with photometric detection at the section of chemical pathology, AKU. Statistical analysis was done using Microsoft Excel (Microsoft Corporation, Washington, United States) and EP Evaluator version 10.3.0.556 (Data Innovations, LLC, VT, US). Quantitative variables were represented in terms of mean ± SD. For precision, the computed SD was compared with allowable random error. Furthermore, Cohen’s kappa was applied to observe the agreement between the two methods. Results The Trop-I Precision study on the POCT analyzer showed a coefficient of variation (CV) of 2.4% using a pooled patient sample with a mean Trop-I of 2.15 ± 0.05 ng/ml. Three standards ranging from 0.034 to 1.316 ng/ml were run in triplicate to verify accuracy and linearity. The allowable systematic error (SEa) was 10.0%. The maximum deviation for a mean recovery from 100% was 4.1%. All three of the mean recoveries were accurate and within the allowable error limits. The results were linear with slope 1.04, intercept 0.0. On a method comparison, Trop-I showed good agreement, yielding a kappa value of 0.95. Conclusion This study has validated the performance of a POCT Trop-I assay against a central laboratory immunoassay and found acceptable results. POCT assays for cTnI should be implanted in emergency settings to ensure the fast triage of patients with chest pain, as well as timely diagnosis.

show abstract

Clinical performance of cardiac Troponin I: A comparison between the POCT AQT90 FLEX and the Dimension Vista analyzer in an emergency setting

Cited by 14 publications

References 12 publications

Serial Troponin for Early Detection of Nivolumab Cardiotoxicity in Advanced Non-Small Cell Lung Cancer Patients

Serial Troponin for Early Detection of Nivolumab Cardiotoxicity in Advanced Non-Small Cell Lung Cancer Patients

Multi-centre evaluation of recent troponin assays for the diagnosis of NSTEMI

Performance Evaluation of Cardiac Troponin I Assay: A Comparison Between the Point-of-care Testing Radiometer AQT90 FLEX and the Central Laboratory Siemens Advia Centaur Analyzer

Contact Info

Product

Resources

About